450 Participants Needed

Lenvatinib + Pembrolizumab + TACE for Liver Cancer

Recruiting at 228 trial locations
TF
Overseen ByToll Free Number
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Pivotal Trial (Near Approval)This treatment is in the last trial phase before FDA approval
Prior Safety DataThis treatment has passed at least one previous human trial
Breakthrough TherapyThis drug has been fast-tracked for approval by the FDA given its high promise

What You Need to Know Before You Apply

What is the purpose of this trial?

The purpose of this study is to evaluate the efficacy and safety of lenvatinib and pembrolizumab in combination with TACE versus TACE plus oral and intravenous (IV) placebos in participants with incurable, non-metastatic hepatocellular carcinoma (HCC). The primary hypotheses are that pembrolizumab plus lenvatinib in combination with TACE is superior to placebo plus TACE with respect to progression-free survival (PFS) and overall survival (OS).

Will I have to stop taking my current medications?

The trial information does not specify if you need to stop taking your current medications. However, it mentions that participants must have adequately controlled blood pressure, which may involve continuing antihypertensive medications.

What makes the Lenvatinib, Pembrolizumab, and TACE treatment unique for liver cancer?

This treatment is unique because it combines Lenvatinib, a drug that targets cancer growth, with Pembrolizumab, an immune system booster, and TACE, a procedure that delivers chemotherapy directly to the liver, offering a novel approach for patients with liver cancer that cannot be surgically removed.12345

What data supports the effectiveness of the treatment Lenvatinib + Pembrolizumab + TACE for liver cancer?

Research shows that combining lenvatinib with pembrolizumab and TACE has promising effects on treating unresectable liver cancer, suggesting it could be effective for patients who cannot have surgery.23567

Who Is on the Research Team?

MD

Medical Director

Principal Investigator

Merck Sharp & Dohme LLC

Are You a Good Fit for This Trial?

This trial is for adults with non-metastatic, incurable liver cancer (HCC) confirmed by radiology or pathology. Eligible participants may have had Hepatitis B or C if treated properly. They must have stable blood pressure and organ function, and their cancer should be limited to the liver but not suitable for curative treatment.

Inclusion Criteria

My liver cancer cannot be cured with surgery or other treatments.
My organs are functioning well.
My blood pressure is under control, with or without medication.
See 3 more

Exclusion Criteria

I have a serious wound or broken bone that isn't healing.
I haven't had major heart problems like heart failure in the last year.
I have had treatment directly on liver tumors.
See 3 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive lenvatinib and pembrolizumab in combination with TACE or placebo plus TACE

Up to 2 years
Pembrolizumab IV every 6 weeks, lenvatinib daily

Follow-up

Participants are monitored for progression-free survival and overall survival

Up to 43 months

Long-term Follow-up

Participants are monitored for disease control rate and adverse events

Up to 95 months

What Are the Treatments Tested in This Trial?

Interventions

  • Lenvatinib
  • Pembrolizumab
  • TACE
Trial Overview The study tests the effectiveness of lenvatinib plus pembrolizumab with TACE against placebo plus TACE in improving survival without cancer progression in patients with HCC. The goal is to see if combining these drugs with TACE leads to better outcomes than TACE alone.
How Is the Trial Designed?
2Treatment groups
Experimental Treatment
Active Control
Group I: Lenvatinib plus Pembrolizumab plus TACEExperimental Treatment3 Interventions
Group II: Oral Placebo plus IV Placebo plus TACEActive Control3 Interventions

Lenvatinib is already approved in United States, European Union for the following indications:

🇺🇸
Approved in United States as Lenvima for:
🇪🇺
Approved in European Union as Lenvima for:
🇪🇺
Approved in European Union as Kisplyx for:

Find a Clinic Near You

Who Is Running the Clinical Trial?

Merck Sharp & Dohme LLC

Lead Sponsor

Trials
4,096
Recruited
5,232,000+
Chirfi Guindo profile image

Chirfi Guindo

Merck Sharp & Dohme LLC

Chief Marketing Officer since 2022

Degree in Engineering from Ecole Centrale de Paris, MBA from New York University Stern School of Business

Robert M. Davis profile image

Robert M. Davis

Merck Sharp & Dohme LLC

Chief Executive Officer since 2021

JD from Northwestern University Pritzker School of Law, MBA from Northwestern University Kellogg Graduate School of Management, Bachelor's in Finance from Miami University

Merck Sharp & Dohme Corp.

Lead Sponsor

Trials
2,287
Recruited
4,582,000+
Chirfi Guindo profile image

Chirfi Guindo

Merck Sharp & Dohme Corp.

Chief Medical Officer

Engineering degree from Ecole Centrale de Paris, MBA from New York University Stern School of Business

Robert M. Davis profile image

Robert M. Davis

Merck Sharp & Dohme Corp.

Chief Executive Officer since 2021

J.D. from Northwestern University Pritzker School of Law, MBA from Northwestern University Kellogg Graduate School of Management, Bachelor's in Finance from Miami University

Eisai Inc.

Industry Sponsor

Trials
524
Recruited
161,000+
Founded
Eisai Inc. was established in 1995 as the U.S. subsidiary of Eisai Co., Ltd.
Headquarters
Woodcliff Lake, NJ, USA
Known For
Neurology and Oncology
Top Products
Aricept (donepezil), Lenvima (lenvatinib), Leqembi (lecanemab), Halaven (eribulin)
Lynn Kramer profile image

Lynn Kramer

Eisai Inc.

Chief Medical Officer since 2019

MD

Tatsuyuki Yasuno profile image

Tatsuyuki Yasuno

Eisai Inc.

Chief Executive Officer since 2023

MBA from Kellogg School of Management, Northwestern University; Bachelor of Political Science from Waseda University

Published Research Related to This Trial

In a study of 71 patients with unresectable hepatocellular carcinoma (uHCC), the combination of lenvatinib and pembrolizumab demonstrated a high disease control rate of 84.1% for first-line treatment, indicating its efficacy in managing this condition.
The treatment did not adversely affect liver function, as measured by the Albumin-Bilirubin (ALBI) score, and factors such as prior nivolumab failure and Child-Pugh class B were associated with poorer progression-free and overall survival, highlighting the need for further investigation in these subgroups.
Lenvatinib plus pembrolizumab for systemic therapy-naïve and -experienced unresectable hepatocellular carcinoma.Wu, CJ., Lee, PC., Hung, YW., et al.[2022]
In a study of 62 patients with unresectable hepatocellular carcinoma (uHCC), the combination of lenvatinib, anti-PD-1 antibodies, and transcatheter arterial chemoembolization (TACE) resulted in a high objective response rate of approximately 80%, indicating strong efficacy in shrinking tumors.
Over half of the patients (53.2%) became eligible for surgical resection after treatment, demonstrating the potential of this triple therapy to convert previously unresectable tumors into resectable ones, with manageable side effects reported in 74.2% of patients.
Lenvatinib Combined with Anti-PD-1 Antibodies Plus Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study.Wu, JY., Yin, ZY., Bai, YN., et al.[2022]

Citations

Lenvatinib plus pembrolizumab for systemic therapy-naïve and -experienced unresectable hepatocellular carcinoma. [2022]
Efficacy and safety of transarterial chemoembolization combined with lenvatinib and camrelizumab in patients with BCLC-defined stage C hepatocellular carcinoma. [2023]
Safety and efficacy of lenvatinib combined with camrelizumab plus transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: A two-center retrospective study. [2022]
Lenvatinib Combined with Anti-PD-1 Antibodies Plus Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study. [2022]
Transarterial Chemoembolization Combined With Lenvatinib Plus PD-1 Inhibitor for Advanced Hepatocellular Carcinoma: A Retrospective Cohort Study. [2022]
Efficacy and Safety of TACE Combined with Lenvatinib and PD-(L)1 Inhibitor in the Treatment of Unresectable Hepatocellular Carcinoma: A Retrospective Study. [2023]
Efficacy and safety of transarterial chemoembolization plus lenvatinib with or without programmed death-1 inhibitors in the treatment of unresectable hepatocellular carcinoma: a systematic review and meta-analysis. [2023]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security